Is the current diagnostic algorithm reliable for selecting cases for EGFR - and KRAS -mutation analysis in lung cancer?
Highlights • EGFR - and KRAS -mutations in lung cancer are relevant for treatment decisions. • Current guidelines do not advise to analyze squamous cell carcinomas. • We examined the fraction of mutations that would have been missed in our database. • 2.0% (2/102) of EGFR - and 1.7% (4/237) of KRAS...
Gespeichert in:
Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-07, Vol.89 (1), p.19-26 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Highlights • EGFR - and KRAS -mutations in lung cancer are relevant for treatment decisions. • Current guidelines do not advise to analyze squamous cell carcinomas. • We examined the fraction of mutations that would have been missed in our database. • 2.0% (2/102) of EGFR - and 1.7% (4/237) of KRAS -mutations would not have been tested. • The percentage is slightly higher than the suggested threshold of 1% for EGFR. |
---|---|
ISSN: | 0169-5002 1872-8332 |
DOI: | 10.1016/j.lungcan.2015.04.005 |